Amica Mutual Insurance Co. Has $4.65 Million Holdings in Zoetis Inc. $ZTS

Amica Mutual Insurance Co. lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 27.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,932 shares of the company’s stock after acquiring an additional 8,026 shares during the quarter. Amica Mutual Insurance Co.’s holdings in Zoetis were worth $4,647,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. RFG Advisory LLC boosted its holdings in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares in the last quarter. YANKCOM Partnership boosted its holdings in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. boosted its holdings in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after acquiring an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its holdings in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. boosted its holdings in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after acquiring an additional 87 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research analyst reports. Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday. Finally, Citigroup dropped their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Stock Performance

Shares of Zoetis stock opened at $77.81 on Friday. The firm has a fifty day moving average of $104.29 and a two-hundred day moving average of $117.03. The stock has a market capitalization of $32.62 billion, a price-to-earnings ratio of 12.90, a PEG ratio of 1.28 and a beta of 0.87. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.89 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Activity at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 11,650 shares of company stock worth $886,384 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.